Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer

PartnershipSpevatamigKEYTRUDAPositive

AI Analysis

Summary

Phanes Therapeutics announced an expansion of its clinical trial collaboration with Merck to evaluate the anti-CLDN18.2/CD47 bispecific antibody Spevatamig in combination with Pembrolizumab and chemotherapy for biliary tract cancer treatment. Spevatamig is currently in Phase 2 studies for multiple forms of gastrointestinal cancers.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Expansion of clinical trial collaboration and supply agreement

Importance:6/10

Sentiment:

0.50

immuno-oncologybispecific antibodyclinical collaborationcombination therapygastrointestinal cancer

Related Companies

$MRK

Read the original article

Published by PR Newswire Biotech on July 21, 2026 10:00 AM

Read Original